Novartis's Kymriah meets endpoint in follicular lymphoma trial

Credit: REUTERS/ARND WIEGMANN

Novartis CAR-T cell therapy Kymriah met its primary endpoint at an interim analysis of a phase-II trial in patients with relapsed or refractory follicular lymphoma, the Swiss drugmaker said on Tuesday. [ID:nGNE4ySMhY]

ZURICH, Aug 4 (Reuters) - Novartis NOVN.S CAR-T cell therapy Kymriah met its primary endpoint at an interim analysis of a phase-II trial in patients with relapsed or refractory follicular lymphoma, the Swiss drugmaker said on Tuesday. ID:nGNE4ySMhY

Findings of the ELARA trial will support regulatory submissions, with filing in the United States anticipated in 2021 and in the European Union afterwards, it said.

(Reporting by Michael Shields Editing by Michelle Martin)

((Michael.Shields@thomsonreuters.com; +41 58 306 7461; Reuters Messaging: michael.shields.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NOVN

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More